Literature DB >> 20854876

MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.

Sara C Monroe1, Stephanie Y Jo, Daniel S Sanders, Venkatesha Basrur, Kojo S Elenitoba-Johnson, Robert K Slany, Jay L Hess.   

Abstract

OBJECTIVE: The aim of this study was to better understand how mixed lineage leukemia (MLL) fusion proteins deregulate the expression of genes critical for leukemia.
MATERIALS AND METHODS: The transforming domain of one of the most common MLL fusion partners, AF9, was immunopurified after expression in myeloblastic M1 cells, and associating proteins were identified by mass spectrometric analysis. Chromatin immunoprecipitation followed by quantitative polymerase chain reaction was used to determine how binding of associating proteins compare across Hoxa9 and Meis1 in cell lines with and without MLL fusion proteins and how binding is altered during gene down-regulation and differentiation.
RESULTS: Consistent with earlier purifications of ENL and AF4 from 293 cells, the 90 amino acid C-terminal domain of AF9 associates with many other MLL translocation partners including Enl, Af4, Laf4, Af5q31, Ell, and Af10. This complex, termed elongation assisting proteins (EAPs), also contains the RNA polymerase II C-terminal domain kinase Cdk9/Cyclin T1/T2 (pTEFb) and the histone H3 lysine 79 methyltransferase Dot1L. Myeloid cells transformed by MLL fusions show higher levels and a broader distribution of EAP components at genes critical for leukemia. Inhibition of EAP components pTEFb and Dot1l show that both contribute significantly to activation of Hoxa9 and Meis1 expression. EAP is dynamically associated with the Hoxa9 and Meis1 loci in hematopoietic cells and rapidly dissociates during induction of differentiation. In the presence of MLL fusion proteins, its dissociation is prevented.
CONCLUSIONS: The findings suggest that MLL fusion proteins deregulate genes critical for leukemia by excessive recruitment and impaired dissociation of EAP from target loci.
Copyright © 2011 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20854876      PMCID: PMC3038424          DOI: 10.1016/j.exphem.2010.09.003

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  31 in total

1.  Empirical statistical model to estimate the accuracy of peptide identifications made by MS/MS and database search.

Authors:  Andrew Keller; Alexey I Nesvizhskii; Eugene Kolker; Ruedi Aebersold
Journal:  Anal Chem       Date:  2002-10-15       Impact factor: 6.986

2.  Leukemogenic MLL fusion proteins bind across a broad region of the Hox a9 locus, promoting transcription and multiple histone modifications.

Authors:  Thomas A Milne; Mary Ellen Martin; Hugh W Brock; Robert K Slany; Jay L Hess
Journal:  Cancer Res       Date:  2005-12-15       Impact factor: 12.701

3.  Analyzing real-time PCR data by the comparative C(T) method.

Authors:  Thomas D Schmittgen; Kenneth J Livak
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

4.  Aberrant chromatin at genes encoding stem cell regulators in human mixed-lineage leukemia.

Authors:  Matthew G Guenther; Lee N Lawton; Tatiana Rozovskaia; Garrett M Frampton; Stuart S Levine; Thomas L Volkert; Carlo M Croce; Tatsuya Nakamura; Eli Canaani; Richard A Young
Journal:  Genes Dev       Date:  2008-12-15       Impact factor: 11.361

Review 5.  Poised RNA polymerase II gives pause for thought.

Authors:  Thanasis Margaritis; Frank C P Holstege
Journal:  Cell       Date:  2008-05-16       Impact factor: 41.582

6.  Lipopolysaccharide activates transcription of the heme oxygenase gene in mouse M1 cells through oxidative activation of nuclear factor kappa B.

Authors:  S Kurata; M Matsumoto; Y Tsuji; H Nakajima
Journal:  Eur J Biochem       Date:  1996-08-01

7.  Flavopiridol inhibits P-TEFb and blocks HIV-1 replication.

Authors:  S H Chao; K Fujinaga; J E Marion; R Taube; E A Sausville; A M Senderowicz; B M Peterlin; D H Price
Journal:  J Biol Chem       Date:  2000-09-15       Impact factor: 5.157

8.  A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription.

Authors:  Akihiko Yokoyama; Min Lin; Alpana Naresh; Issay Kitabayashi; Michael L Cleary
Journal:  Cancer Cell       Date:  2010-02-17       Impact factor: 31.743

9.  Mouse Af9 is a controller of embryo patterning, like Mll, whose human homologue fuses with Af9 after chromosomal translocation in leukemia.

Authors:  Emma C Collins; Alexandre Appert; Linda Ariza-McNaughton; Richard Pannell; Yoshihiro Yamada; Terence H Rabbitts
Journal:  Mol Cell Biol       Date:  2002-10       Impact factor: 4.272

10.  Chromatin immunoprecipitation (ChIP) for analysis of histone modifications and chromatin-associated proteins.

Authors:  Thomas A Milne; Keji Zhao; Jay L Hess
Journal:  Methods Mol Biol       Date:  2009
View more
  42 in total

1.  MLL leukemia induction by genome editing of human CD34+ hematopoietic cells.

Authors:  Corina Buechele; Erin H Breese; Dominik Schneidawind; Chiou-Hong Lin; Johan Jeong; Jesus Duque-Afonso; Stephen H K Wong; Kevin S Smith; Robert S Negrin; Matthew Porteus; Michael L Cleary
Journal:  Blood       Date:  2015-08-26       Impact factor: 22.113

2.  Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.

Authors:  Fang Cao; Elizabeth C Townsend; Hacer Karatas; Jing Xu; Li Li; Shirley Lee; Liu Liu; Yong Chen; Peter Ouillette; Jidong Zhu; Jay L Hess; Peter Atadja; Ming Lei; Zhaohui S Qin; Sami Malek; Shaomeng Wang; Yali Dou
Journal:  Mol Cell       Date:  2014-01-02       Impact factor: 17.970

Review 3.  The pathogenesis of mixed-lineage leukemia.

Authors:  Andrew G Muntean; Jay L Hess
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

4.  Mechanisms of mixed-lineage leukemia.

Authors:  Andrew G Muntean
Journal:  Int J Hematol Oncol       Date:  2013-06-01

5.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

Review 6.  The molecular mechanics of mixed lineage leukemia.

Authors:  R K Slany
Journal:  Oncogene       Date:  2016-02-29       Impact factor: 9.867

7.  Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Christina R Majer; Christopher J Sneeringer; Jeffrey Song; L Danielle Johnston; Margaret Porter Scott; Jesse J Smith; Yonghong Xiao; Lei Jin; Kevin W Kuntz; Richard Chesworth; Mikel P Moyer; Kathrin M Bernt; Jen-Chieh Tseng; Andrew L Kung; Scott A Armstrong; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Cancer Cell       Date:  2011-07-12       Impact factor: 31.743

8.  Proteomic approaches for cancer epigenetics research.

Authors:  Dylan M Marchione; Benjamin A Garcia; John Wojcik
Journal:  Expert Rev Proteomics       Date:  2018-11-27       Impact factor: 3.940

9.  An Af9 cis-element directly targets Dot1a to mediate transcriptional repression of the αENaC gene.

Authors:  Wenzheng Zhang; Zhiyuan Yu; Hongyu Wu; Lihe Chen; Qun Kong; Bruce C Kone
Journal:  Am J Physiol Renal Physiol       Date:  2012-11-14

10.  Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology.

Authors:  Venita Gresham Watson; Katherine M Drake; Yu Peng; Andrew D Napper
Journal:  Assay Drug Dev Technol       Date:  2013-05       Impact factor: 1.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.